{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036391","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.574312+00:00","generated_at":"2026-06-04T07:58:18.572339+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance","bullets":["Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.","Received 180-day extension until September 22, 2024 to regain $1.00 minimum bid price compliance.","Company had failed to meet bid price requirement by March 25, 2024 compliance date.","GLTO continues trading under same symbol; reverse stock split is under consideration.","If not compliant by September 22, Nasdaq may delist; company could appeal to hearings panel."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036391","json":"https://secwatch.observer/filing/0000950170-24-036391.json","markdown":"https://secwatch.observer/filing/0000950170-24-036391.md","text":"https://secwatch.observer/filing/0000950170-24-036391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017024036391/0000950170-24-036391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017024036391/glto-20240322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:58:18.572339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}